Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
Rohini Sharma(Hammersmith Hospital), Hani Gabra(Royal Children's Hospital), Ada E. Brooks(Ovarian Cancer Action), Hugh Mitchell(Pacific Northwest National Laboratory), Sarah P. Blagden(Churchill Hospital), John D. Graham(Charles Sturt University)
Cited by 65
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
|The Lancet|2005|447
Failed lumbar disc surgery and repeat surgery following industrial injuries.
|Journal of Bone and Joint Surgery|1979|290